Vial Announces Dosing of First Patient in Phase 1 Healthy Volunteer Trial
Vial Logo
Back to Resources
  • Videos

Dr. JiaDe Yu, Chair of Dermatology and Associate Professor at Virginia Commonwealth University School of Medicine, highlights how dual inhibition of IL-13 and TSLP could advance care for patients with atopic dermatitis, delivering stronger efficacy than targeting either pathway alone.

More Resources

Dr. Arya M. Sharma, MD, DSc (hon), FRCPC, FCAHS, Emeritus Professor of Medicine at the University of Alberta, highlights INHBE as a promising new target for obesity, acting on both adipocytes and hepatocytes to drive fat-selective weight loss.

Dr. JiaDe Yu, Chair of Dermatology and Associate Professor at Virginia Commonwealth University School of Medicine, highlights how dual inhibition of IL-13 and TSLP could advance care for patients with atopic dermatitis, delivering stronger efficacy than targeting either pathway alone.

It’s clear the next breakthrough in obesity treatment will come from entirely new mechanisms that go beyond appetite suppression like VIAL-INHBE. Hear more from Dr. Jens Juul Holst, Professor at the Department of Biomedical Sciences and Senior Group Leader at Novo Nordisk Foundation Center for Basic Metabolic Research.

Connect with us.

Interested in receiving a proposal from Vial? Leave us a message and some of your contact info and we’ll be in touch with you shortly.

This field is for validation purposes and should be left unchanged.
Name(Required)
By submitting, you are agreeing to our terms and privacy policy

Contact Us

This field is for validation purposes and should be left unchanged.
Name(Required)
By submitting, you are agreeing to our terms and privacy policy